|Salary:||£28,208 per annum (pro-rata), inclusive of London Allowance.|
|Placed On:||1st October 2021|
|Closes:||15th October 2021|
About the Role
We are looking for a motivated and hard working person to develop a very exciting project in collaboration with Achilles Therapeutics. The post holder will be responsible to isolate human primary T cells and study their metabolism via our dedicated mass spectrometry facility. In this project, Achilles and QMUL will work together to define the metabolic signature of exhausted T-cells, with the aim to identify pathways important for the optimal growth of all tumour infiltrating lymphocytes (TIL). The identification of key products of metabolism that correlate with cells at different stages of differentiation is fundamental to track the “health” of tumour-reactive T-cell to avoid T-cell exhaustion and prevent their loss.
- The post holder will also have to keep accurate written and computerised records of all work.
- The post holder must at all times carry out their responsibilities with due regard to Queen Mary's Equal Opportunities policy.
- To demonstrate a commitment to continuing professional development and will participate in the Queen Mary Appraisal Scheme.
The ideal candidate holds a BSc or equivalent in relevant biological sciences. Previous experience working in a research lab and/or with primary human cells would be an advantage. Also desirable is knowledge of basic and tumour immunology as well as cellular metabolism.
About the School/Department/Institute/Project
The Barts Cancer Institute (BCI) is a Cancer Research UK Centre of Excellence whose work aims to transform the lives of those with and at risk of cancer through innovative research in the laboratory, in patients and in populations. BCI is internationally renowned in many areas of cancer research and it combines ground-breaking basic research with the expertise of clinicians and clinician scientists from the Centre for Experimental Cancer Medicine and the Barts NHS Trust to achieve improvements in cancer patient care. BCI is also a partner in the CRUK City of London Major Centre (together with UCL, Kings and the Francis Crick Institute) which is a Centre of Excellence in Biotherapeutics. BCI is committed in supporting and developing future cancer researchers through its extensive postgraduate training.
We offer competitive salaries, access to a generous pension scheme, 30 days’ leave per annum (pro-rata for part-time/fixed-term), a season ticket loan scheme and access to a comprehensive range of personal and professional development opportunities. In addition, we offer a range of work life balance and family friendly, inclusive employment policies, flexible working arrangements, and campus facilities including an on-site nursery at the Mile End campus.
The post is based at the Charterhouse square Campus in London. It is full time (35 hours per week), fixed term appointment for 8 months, with an expected start date of November 2021. The starting salary will be Grade 3, £28,208 per annum (pro-rata), inclusive of London Allowance.
Queen Mary’s commitment to our diverse and inclusive community is embedded in our appointments processes. Reasonable adjustments will be made at each stage of the recruitment process for any candidate with a disability. We are open to considering applications from candidates wishing to work flexibly.
Informal enquiries should be addressed to Katiuscia Bianchi at firstname.lastname@example.org
To apply for the role, please click the ‘apply’ button.
The closing date for applications is 15 October 2021.
Interviews are expected to be held on shortly thereafter.
Type / Role: